{"id":205288,"date":"2026-05-05T14:53:42","date_gmt":"2026-05-05T14:53:42","guid":{"rendered":"https:\/\/www.welovecycling.com\/wide\/?p=205288"},"modified":"2026-05-05T14:53:42","modified_gmt":"2026-05-05T14:53:42","slug":"research-shows-what-happens-when-you-stop-taking-ozempic","status":"publish","type":"post","link":"https:\/\/www.welovecycling.com\/wide\/2026\/05\/05\/research-shows-what-happens-when-you-stop-taking-ozempic\/","title":{"rendered":"New Research Shows What Happens When People Stop Taking Ozempic"},"content":{"rendered":"

A large analysis from the Cleveland Clinic, involving nearly 8,000 patients, challenges the assumption that stopping GLP-1 weight-loss drugs like Ozempic inevitably leads to rapid weight regain. Instead, the study reveals a more nuanced reality. Let\u2019s take a closer look.<\/strong><\/p>\n

<\/p>\n

Real-world outcomes vs. clinical trials<\/strong><\/h2>\n

Earlier randomised clinical trials painted a grim picture: patients who stopped GLP-1 drugs based on compounds like semaglutide (Ozempic) or tirzepatide (Mounjaro) regained more than half of their lost weight within a year. However, this new real-world study, published in Diabetes, Obesity and Metabolism,<\/a> suggests that everyday clinical practice tells a different story. Here, patients have the flexibility to adjust their treatment plans, often with the support of healthcare providers.<\/p>\n

\u201cOur real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomised trials,\u201d explains Hamlet Gasoyan, the study\u2019s lead researcher.<\/p>\n

The numbers: weight loss, regain, and stability<\/strong><\/h2>\n

The study tracked 7,938 adults with overweight or obesity in Ohio and Florida, all of whom had started and then stopped GLP-1 treatments within 3 to 12 months. The results were striking. Patients treated for obesity:<\/p>\n